For the year ending 2025-12-31, FULC has $366,284K in assets. $17,284K in debts. $197,533K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 197,533 | |||
| Marketable securities | 154,773 | |||
| Unbilled accounts receivable | 0 | |||
| Prepaid expenses and other current assets | 5,174 | |||
| Total current assets | 357,480 | |||
| Total property and equipment | 18,471 | |||
| Less accumulated depreciation | 15,647 | |||
| Property and equipment, net | 2,824 | |||
| Operating lease right-of-use assets | 4,241 | |||
| Restricted cash | 1,201 | |||
| Other assets | 538 | |||
| Total assets | 366,284 | |||
| Accounts payable | 1,592 | |||
| Accrued expenses and other current liabilities | 9,052 | |||
| Operating lease liability, current | 2,404 | |||
| Total current liabilities | 13,048 | |||
| Operating lease liability, excluding current portion | 4,039 | |||
| Other liabilities, excluding current portion | 197 | |||
| Total liabilities | 17,284 | |||
| Common stock, 0.001 par value 200,000,000 shares authorized 66,578,891 and 53,968,303 shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively | 67 | |||
| Additional paid-in capital | 943,037 | |||
| Accumulated other comprehensive gain | 174 | |||
| Accumulated deficit | -594,278 | |||
| Total stockholders equity | 349,000 | |||
| Total liabilities and stockholders equity | 366,284 | |||
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)